Osamu Yokosuka is an Emeritus Professor of Chiba University, Japan. He graduated from Chiba University School of Medicine in 1975 then worked as a trainee under Professor K. Okuda in Chiba University Hospital till 1978. Dr. Yokosuka was a research fellow worked under Professor S. Scherlock and Professor B. H. Billing in Royal Free Hospital, London, UK from 1978 to 1980; under Professor M. Omata in Chiba University from 1980 to 1985; and under Dr. J Summers in Fox Chase Cancer Center, PA, USA in 1984. In 1985, he received a Degree of Doctor of Medical Science, and served as an Assistant Professor in Chiba University till 1994, then as Lecturer in Medicine till 2006 when he was appointed as Director and Professor of Medicine. From 2013 to 2015, he served as the Dean of Chiba University School of Medicine.
Dr. Yokosuka was the Secretary General of APASL (2008-2014). In 2016, he was elected as the President of APASL Tokyo, the President of 52nd Annual Meeting of Japan Society of Hepatology, and the President of Funabashi Central Hospital. Dr. Yokosuka’s research mainly focuses on Hepatitis and Hepatocellular Carcinoma. So far, he has published more than 700 original papers.
Tatsuo Kanda received a medical degree in 1991 at Niigata University School of Medicine, Japan, and his PhD in 1999 at Chiba University Graduate School of Medicine, Japan. He had post-doctor training for 3 years under Prof. Ratna Ray and Prof. Ranjit Ray at Saint Louis University, St. Louis, MO, USA. In Dec. 2008, Tatsuo Kanda became a Tenure-track Associate Professor at Department of Medicine and Clinical Oncology, Chiba University, Graduate School of Medicine, Japan. In Feb. 2013, Tatsuo Kanda was nominated a permanent Associate Professor at Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Japan. In 2017, Tatsuo Kanda became an Associate Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine. For ~25 years, he has focused his scientific interests on the topics related to liver diseases including acute liver failure, viral hepatitis and autoimmune liver diseases, and worked with Prof. Osamu Yokosuka. Tatsuo Kanda is also an expert for hepatitis A virus (HAV), HBV and HCV, and translation and replication of these viruses, and hepatocarcinogenesis. With his expertise in antiviral therapies and hepatitis virus research, Tatsuo Kanda also sees a lot of patients in clinical daily practice. Tatsuo Kanda has published more than 200 articles in peer-reviewed Journal.
Zhao Yang Dong (M’99–SM’06-F'17) obtained Ph.D. degree from the University of Sydney, Australia in 1999. He is currently the SHARP professor and Director of the University of New South Wales Digital Grid Futures Institute, The University of New South Wales, Australia. He is also Director for ARC Research Hub for Integrated Energy Storage Solutions. He was previously Professor and Head of School of Electrical and Information Engineering, University of Sydney, and Ausgrid Chair and Director of the Ausgrid Centre for Intelligent Electricity Networks, the University of Newcastle, Australia. He also held industrial positions with Transend Networks (now TAS Networks), Australia. His research interests include smart grid, power system planning, power system security, renewable energy systems, electricity market, load modelling, and computational intelligence and its application in power engineering. He is serving/served as an editor of IEEE Transactions on Smart Grid, IEEE Power Engineering Letters, and IET Renewable Power Generation.HE is Fellow of IEEE.
Current Advancement of Islet Cell Transplantation in the Treatment of Diabetes Mellitus
Submission Deadline: September 30, 2018 (Open) Submit Now
Kenneth L. Brayman, MD, PhD, FACS
About This Topic
OBM Transplantation is an international peer-reviewed Open Access journal, which covers all evidence-based scientific studies related to transplantation. This is seeking original manuscripts for a Special Issue on cell-based therapy for diabetes: “Current Advancement of Islet Cell Transplantation in the Treatment of Diabetes mellitus” scheduled to appear in the first half of 2018.
Islet transplantation and pancreas transplantation have been becoming promising therapies for diabetes, which can restore normal blood glucose and prevent diabetes complications. However, there are many grand challenges for maintaining long-term graft function and insulin independence in diabetes patients.
The special issue will provide a forum for presenting current research works and clinical results showing advancement of cell-based therapy for diabetes, including auto-transplantation, all-transplantation, inflammatory reaction involved islet transplantation, islet macro and microencapsulation, stem cell therapy, as well as in vitro and in vivo imaging of the islets. The special issue will also be open to any author, but mainly invited by guest editor. Each submission will be reviewed by at least two reviewers to ensure a very high quality of papers selected for the Special Issue.
Title: Introduction of the Special Issue
Title: Pancreatic Allo Islet Transplantation: Update on Current Condition
Title: The Role of Auto Islet Transplantation in the Prevention of the Development of Diabetes Mellitus after Total Pancreatectomy
Title: Inflammatory Reaction in Islet Transplantation
Title: Can An Islet be "Isolated" from the Immune System by Encapsulation?
Title: Stem-Cell Therapy in Islet and Pancreas Transplantation
Title: Role of Artificial Pancreas in islet Transplantation
Title: Scaffolding for Diabetes: Reality or Myth.
Title: In Vitro and In vivo Imaging for Diabetes Research and Treatment
Title: Islet Xenotransplantation for the Treatment of Type 1 Diabetes
Title: Autoimmunity in Autologous Islet Transplantation
Title: Intrapancreatic parenchymal cell transplantation (IPPCT) as a useful tool for study in cell-based therapy towards type I diabetes
Title: Delayed clinically significant portal hypertension after TPIAT
Title: Microbiology of High Risk Patients After Pancreatectomy and Autologous Islet Transplant
Title: Nuclear Factor Erythroid-derived 2-like 2 (Nrf-2) Pathway is a Promising Target to Enhance Outcome of Pancreatic Islet Transplantation
Title: Targeting acute islet inflammation to preserve graft mass and long-term function
Title: Chemical Strategies for Improving Islet Transplant Outcomes
Title: Evolution of enzyme requirements for human islet isolation
Title: Where is Waldo? The best place to implant Islets